Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer

Kouichirou Aida,1,2 Reina Miyakawa,1 Koji Suzuki,1 Kenta Narumi,1 Takeshi Udagawa,1,2 Yuki Yamamoto,1 Tatsuya Chikaraishi,2 Teruhiko Yoshida3 and Kazunori Aoki1

1Division of Gene and Immune Medicine, National Cancer Center Research Institute, Tokyo; 2Department of Urology, St. Marianna University, Kanagawa; 3Division of Genetics, National Cancer Center Research Institute, Tokyo, Japan

Key words
Anti-glucocorticoid induced TNF receptor antibody, interferon-α gene therapy, pancreatic cancer

Correspondence
Kazunori Aoki, Division of Gene and Immune Medicine, National Cancer Center Research Institute, S-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Tel: +81-3-3542-2511; Fax: +81-3-3248-1631;
E-mail: kaoki@ncc.go.jp

Funding information
Ministry of Health, Labour and Welfare of Japan
National Institute of Biomedical Innovation.
National Cancer Center Research and Development Fund (23-A-38).

Received August 8, 2013; Revised November 25, 2013; Accepted November 27, 2013
Cancer Sci 105 (2014) 159–167
doi: 10.1111/cas.12332

We have reported that interferon (IFN)-α can attack cancer cells by multiple antitumor mechanisms including the induction of direct cancer cell death and the enhancement of an immune response in several pancreatic cancer models. However, an immunotolerant microenvironment in the tumors is often responsible for the failure of the cancer immunotherapy. Here we examined whether the suppression of regulatory T cells (Tregs) within tumors can enhance an antitumor immunity induced by an intratumoral IFN-α gene transfer. First we showed that an intraperitoneal administration of an agonistic anti-glucocorticoid induced TNF receptor (GITR) monoclonal antibody (mAb), which is reported to suppress the function of Tregs, significantly inhibited subcutaneous tumor growth in a murine pancreatic cancer model. The anti-GITR mAb was then combined with the intratumoral injection of the IFN-α-adenovirus vector. The treatment with the antibody synergistically augmented the antitumor effect of IFN-α gene therapy not only in the vector-injected tumors but also in the vector-uninjected tumors. Immunostaining showed that the anti-GITR mAb decreased Foxp3+ cells infiltrating in the tumors, while the intratumoral IFN-α gene transfer increased CD4+ and CD8+ T cells in the tumors. Therefore, the combination therapy strongly inclined the immune balance of the tumor microenvironment in an antitumor direction, leading to a marked systemic antitumor effect. The CCR5 expression on Tregs was downregulated in the antibody-treated mice, which may explain the decrease of tumor-infiltrating Tregs. The combination of Treg-suppression by GITR mAb and the tumor immunity induction by IFN-α gene therapy could be a promising therapeutic strategy for pancreatic cancer.

Overcoming pancreatic cancer remains one of the most formidable challenges in oncology today despite recent advances in therapeutic and diagnostic modalities.1–3 It is expected to continue to be one of the five leading causes of cancer-related death in Japan, with <5% of patients alive 5 years after diagnosis.4 Its high mortality is due to the high incidence of metastatic disease at the time of diagnosis, a fulminating clinical course, and the lack of adequate systemic therapies.1–3 Pancreatic cancer must be considered as a systemic disease, and new therapeutic approaches that can effectively target this cancer spread in vivo are urgently needed.2,3,5

The interferon (IFN)-α protein is a pleiotropic cytokine regulating anti-proliferation, induction of cell death, anti-angiogenesis and immunomodulation, and has been used for treatment in a variety of cancers such as chronic myeloid leukemia, melanoma and renal cancer.6–8 Although IFN-α was long thought to act mainly by suppressing tumor cell proliferation in vivo, more recently it has been established that type I IFNs have important roles in regulating the innate and adaptive arms of the immune system: upregulation of major histocompatibility complex class I gene, promotion of the priming and survival of T cells, enhancement of humoral immunity, and increase of the cytotoxic activity of natural killer (NK) cells and CD8+ T cells.9,10 We also reported that an intratumoral IFN-α gene transfer elicits a systemic tumor-specific immunity in several animal models11–15 and showed that dendritic cells (DCs) in tumors have a critical role: (i) intratumoral expression of IFN-α effectively induces cell death of cancer cells and exposes tumor associated antigens in large quantity to DCs; (ii) IFN-α promotes maturation of CD11c+ cells, which facilitates the presentation of TAAs on CD11c+ cells; (iii) CD11c+ cells in tumors transduced with the IFN-α gene produce a large quantity of immune-stimulatory cytokines such as IL-1214,16,17 Furthermore, intratumoral gene transfer allows an increased and sustained local concentration of IFN-α in tumors, with
minimal leakage of the cytokine into the systemic blood circulation (11,12,14). Our data showed that, due to the effective induction of antitumor immunity and the lower toxicity, an intratumoral route of the IFN vector is superior to an intravenous administration. (14)

The development of an effective cancer immunotherapy is, however, often difficult because cancer generates an immunotolerant microenvironment against the host immune system. (18)

Regarding this microenvironment, extensive studies have shown that CD4+Foxp3+ regulatory T cells (Tregs) are critical in controlling antitumor immune responses. (19) Therefore, Treg modulation is a promising strategy for enhancing the efficacy of cancer immunotherapy. (20) Recently, it has been reported that anti-glucocorticoid induced tumor necrosis factor receptor (GITR), a type I transmembrane protein with homology to tumor necrosis factor receptor family members, was a molecule that inhibits T-cell receptor-induced apoptosis. (21) GITR is a co-stimulatory molecule expressed at different levels in resting CD4+ and CD8+ T cells and is upregulated after T-cell activation. (21,22) Anti-glucocorticoid induced tumor necrosis factor receptor is also constitutively expressed on CD4+CD25+ Tregs at high levels, and it has been shown that activation of GITR signaling by GITR ligand or agonistic antibody can inhibit the suppressive activity of Tregs attributable to both the co-stimulatory activity of GITR on responder CD4+CD25+ T cells and a direct effect on CD4+CD25+ Tregs. (21–23)

In this study, we examined antitumor effects of agonistic anti-GITR monoclonal antibody (mAb) and intratumoral IFN-α gene transfer in a murine pancreatic cancer model, and showed that the treatment with anti-GITR mAb synergistically enhances the antitumor effect of IFN-α gene therapy for pancreatic cancer. The combination of an induction of tumor immunity and a blockade of the immunotolerant microenvironment could be a promising therapeutic strategy for patients with pancreatic cancer.

Materials and Methods

Tumor cell lines and recombinant adenovirus vectors. Pan02 (H-2b; National Cancer Institute, Frederick, MD, USA) and CT26 (H-2d; American Type Culture Collection, Rockville, MD, USA) are a C57BL/6-derived pancreatic cancer cell line and a BALB/c-derived colon cancer cell line, respectively. They were maintained in an RPMI1640 (Nissui Pharmaceutical, Tokyo, Japan) containing 10% fetal bovine serum (FBS), 2 μM L-glutamine and 0.15% sodium bicarbonate (complete RPMI). The recombinant adenovirus vectors expressing mouse interferon-α (Ad-mIFN) and alkaline phosphatase cDNA (Ad-AP) were prepared as described. (12) The recombinant adenoviruses are based on serotype 5 with deletions of the entire E1 and a part of the E3 regions, and have the CAG promotor, which is a hybrid of the cytomegalovirus immediate early enhancer sequence and the chicken β-actin/rabbit β-globin promotor. (24) A cesium chloride-purified virus was desalted using a sterile Bio-Gel P-6 DG chromatography column (Econopac DG 10; BioRad, Hercules, CA, USA) and diluted for storage in a 13% glycerol/PBS solution. All viral preparations were confirmed by PCR assay to be free of the E1α adenovirus.

Animals and tumor inoculation. Five-to-seven week-old female C57BL/6 (H-2b) and BALB/c (H-2d) mice were purchased from Charles River Japan (Kanagawa, Japan). Female (C57BL/6 × BALB/c) F1 mice (H-2bd) were purchased from Japan SLC Inc. (Hamamatsu, Japan), and were housed under sterilized conditions. Animal studies were carried out according to the Guideline for Animal Experiments of the National Cancer Center Research Institute and approved by the Institutional Committee for Ethics in Animal Experimentation. Pan02 (5 × 10⁶) and CT26 cells (1 × 10⁶) were injected subcutaneously into the legs of C57BL/6 and BALB/c mice, respectively. When a subcutaneous tumor was established (~1.0 cm in diameter), it was directly injected once with Ad-mIFN or control vector (Ad-AP). The tumor volume was calculated using the formula: tumor volume = 1/2 × [ (the shortest diameter)² × (the longest diameter) ]. Data are presented as mean ± standard deviation (SD).

ELISPOT assays. Interferon-γ ELISPot kit (BD Biosciences, San Jose, CA, USA) was used according to the manufacturer’s instructions. Briefly, splenocytes (1 × 10⁶) and mitomycin C (MMC)-treated tumor cells (1 × 10⁶) or syngeneic lymphocytes were co-cultured in 96-well plates pre-coated with mouse IFN-γ (BD Biosciences) for 20 h at 37°C in complete RPMI medium in triplicate. The syngeneic lymphocytes were used to examine whether the therapy induces an autoimmune reaction. After the wells were washed, biotinylated anti-mouse IFN-γ antibody (2 μg/mL) was added and incubated for 2 h at room temperature. A streptavidin-horseradish peroxidase solution was then added and incubated for 1 h at room temperature. After the addition of an aminoethyl carbazole substrate solution, spots were counted under a stereomicroscope.

Flow cytometry of cell surface marker and intracellular cytokine staining. Allo-phycocyanin (APC)-conjugated monoclonal antibody (mAb) to identify mouse IFN-γ and fluorescein isothiocyanate (FITC)-conjugated mAb to detect CD4, CD8 and CCR5 were purchased from BD Biosciences. Splenocytes (1 × 10⁶) were incubated with medium alone (control) or Pan02 (1 × 10⁷) cells for 2 days; brefeldin-A (10 μg/mL) was then added for 2 h of incubation. After being washed, the cells were incubated with the CD4, CD8 or CCR5 mAbs in a total volume of 100 μL PBS with 5% FBS for 30 min at 4°C. CD4 or CD8 stained cells were then fixed and permeabilized with a permeabilization buffer (BD Biosciences), and were finally stained with antibody to IFN-γ for 15 min at room temperature, washed again and analyzed by FACScalibur (BD Biosciences). Irrrelevant IgG mAbs were used as a negative control. Ten thousand live events were acquired for analysis.

Immunohistochemistry. Immunostaining was performed using streptavidin-biotin-peroxidase complex techniques (Nichirei, Tokyo, Japan). Consecutive cryostat tissue sections (6 μm) were mounted on glass slides and fixed in ethanol for 20 min. After blocking with normal rabbit serum, the sections were stained with rat anti-mouse CD4, CD8 and Foxp3 antibodies (BD Biosciences). Parallel negative controls with antibodies of the same isotype were examined in all cases. The sections were counter-stained with methylgreen.

RT-PCR of CCL3, CCL4 and CCL5 genes. To examine the expression of CCR5 ligands such as CCL3, CCL4 and CCL5 in Pan02 subcutaneous tumors, reverse transcriptase (RT)-PCR amplification was carried out using total RNA from the tumors in a 50 μL PCR mixture with the following primer sets: CCL3 upstream (5′-TTCTGTGACAGCCTCCGCTT-3′), CCL3 downstream (5′-ATGAGCCTGCAAGACTGCTT-3′), CCL4 upstream (5′-CCCACCTCCGCTGTTT-3′), CCL4 downstream (5′-GAGAGGGCCCTCCTGTA-3′), CCL5 upstream (5′-TCCCAAGAGGATGTTGCT-3′), CCL5 downstream (5′-GCAGGCTAGATGCGC-3′) primers. In total, 30 cycles
(β-actin: 25 cycles) of the PCR were carried out at 95°C for 30 s, 60°C for 30 s and 72°C for 1 min. The PCR products were fractionated on 2.0% agarose gel.

Statistical analysis. Comparative analyses of the data were performed by the Student’s t-test, using SPSS statistical software (SPSS Japan, Tokyo, Japan). P < 0.05 was considered as a significant difference.

Results

Antitumor effect of intratumoral injection of Ad-mIFN. To examine the in vivo antitumor effect of the IFN-α gene transduction, various amounts (1 × 10⁷, 5 × 10⁷, and 5 × 10⁸ PFU) of Ad-mIFN were injected into the right tumors in the mice with Pan02 tumors on both legs. The injection showed remarkable tumor suppressive effects not only in the vector-injected right tumors but also in the vector-uninjected left tumors in a dose-dependent manner (Fig. 1). The tumor suppressive effect was stronger in the right tumors than in the left tumors, possibly due to the direct anti-proliferative effect of IFN-α in Pan02 cells (data not shown) in addition to an induction of antitumor immunity. Tumor volumes were not changed in the mice treated by intratumoral injection of Ad-AP at 5 × 10⁸ PFU as compared with the no treatment group (Fig. 1).

Intraperitoneal administration of anti-glucocorticoid induced TNF receptor monoclonal antibody suppressed the tumor growth. To examine whether the blockade of GITR-GITR ligand interaction was able to inhibit the tumor growth of Pan02 subcutaneous tumors, an agonistic anti-GITR mAb (DTA-1: 100 μg) was intraperitoneally injected into the mice with right-leg Pan02 tumors. This significantly suppressed tumor growth as compared with the control IgG injection (Fig. 2a). Then, to examine the expansion of tumor-responsive lymphocytes after the injection of GITR mAb, the splenocytes were harvested 14 days after the antibody administration, and stimulated with MMC-treated Pan02 cells or syngeneic lymphocytes. An ELISpot assay showed that the anti-GITR mAb significantly increased the number of IFN-γ-secreting cells in response to Pan02 cells but not to syngeneic lymphocytes compared with the control IgG treatment (Fig. 2b), suggesting...

Fig. 1. Adenovirus-mediated intratumoral interferon (IFN)-α gene transfer induces a systemic antitumor effect. Pan02 cells were inoculated on both legs in C57BL/6 mice, and 11 days later various amounts (1 × 10⁷, 5 × 10⁷, 5 × 10⁸ PFU) of Ad-mIFN or Ad-AP were injected into the subcutaneous tumor on the right leg (n = 4). Data are representative of two separate experiments with similar results.

Fig. 2. Intraperitoneal injection of anti-glucocorticoid induced TNF receptor (GITR) monoclonal antibody (mAb) suppresses the growth of pancreatic cancer tumors. (a) Pan02 cells were inoculated on the right legs in C57BL/6 mice, and 6 days later 100 μg of anti-GITR mAb was intraperitoneally injected into the mice (n = 3). Data are representative of two separate experiments with similar results. (b) The increase of interferon (IFN)-γ-positive cells in response to stimulation of Pan02 cells by an ELISpot assay. Two weeks after the injection of anti-GITR mAb, splenocytes were isolated from treated mice, and co-cultured with Pan02 cells or control lymphocytes (n = 3).
that the blockade of GITR effectively expanded tumor-responsive immune cells.

Combination therapy of anti-glucocorticoid induced TNF receptor monoclonal antibody and intratumoral IFN-\(\alpha\) gene transfer showed an augmented antitumor activity. To ascertain whether the combination of anti-GITR mAb enhances an antitumor immunity induced by the intratumoral IFN-\(\alpha\) gene transfer, the antibody was intraperitoneally administered at day 6 after the subcutaneous inoculation of Pan02 cells followed by intratumoral injection of Ad-mIFN at day 11. The injection of a lower dose (1 \(\times\) 10^7 PFU) of Ad-mIFN showed the tumor suppressive effects not only in vector-injected right tumors but also in the vector-uninjected left tumors in anti-GITR mAb-treated mice compared with the injection of Ad-AP (Fig. 3a). Furthermore, the higher dose (5 \(\times\) 10^7 PFU) of Ad-mIFN with anti-GITR mAb showed the stronger suppressive effect of Pan02 tumor growth at both sites compared with the lower dose adenovirus injection (Fig. 3b).

To confirm the antitumor activity of the combination therapy in a different tumor cell line, 3 \(\times\) 10^7 PFU of Ad-mIFN was injected into CT26 tumor-bearing mice after the administration of anti-GITR mAb. The antitumor activity of combination therapy was also evident against the colon cancer cells (Fig. 3c). Then, we subcutaneously inoculated Pan02 cells on the right legs and CT26 cells on the left legs of (C57BL/6 \(\times\) BALB/c) F1 mice. The 30 \(\mu\)g of DTA-1 antibody was intraperitoneally injected into the mice at day 6, and then 5 \(\times\) 10^7 PFU of Ad-mIFN was injected into the right Pan02 tumors at day 11. The combination therapy significantly suppressed the Pan02 tumor growth compared with the no treatment, GITR antibody alone and the Ad-mIFN alone groups, whereas the effect was not recognized in the CT26 tumors.

![Fig. 3. Anti-glucocorticoid induced TNF receptor (GITR) monoclonal antibody (mAb) enhances the antitumor immunity of intratumoral interferon (IFN)-\(\alpha\) gene transfer. Data are representative of at least two separate experiments with similar results.](www.wileyonlinelibrary.com/journal/cas)
An ELISpot assay showed that the average number of IFN-γ-producing splenocytes in response to Pan02 cells was increased in the Ad-mIFN alone group, whereas the combination therapy further increased the IFN-γ-positive spots (Fig. 4a). The numbers of spots in splenocytes co-cultured with syngeneic lymphocytes were not changed in the treated groups (Fig. 4a). In fact, all treated mice looked healthy during the course of experiments and blood chemistry showed no abnormal values in the treated mice at 4 weeks (data not shown), indicating that the combination therapy did not induce autoimmunity. To analyze the subset of activated lymphocytes, the frequency of tumor-responsive immune cells was determined by intracellular cytokine staining and flow cytometry. The percentage of CD4+ and CD8+ T cells stimulated to produce IFN-γ in response to Pan02 cells increased significantly in the mice treated by the combination therapy (Fig. 4b), indicating that this therapy enhances systemic antitumor immunity.

**Combination therapy of anti-glucocorticoid induced TNF receptor monoclonal antibody and intratumoral IFN-α gene transfer increased the tumor-responsive T cells.** To examine the *in vivo* immune reaction by the combination therapy, splenocytes were collected from the treated mice and cultured with Pan02 cells. An ELISpot assay showed that the average number of IFN-γ-producing splenocytes in response to Pan02 cells was increased in the Ad-mIFN alone group, whereas the combination therapy further increased the IFN-γ-positive spots (Fig. 4a). The numbers of spots in splenocytes co-cultured with syngeneic lymphocytes were not changed in the treated groups (Fig. 4a). In fact, all treated mice looked healthy during the course of experiments and blood chemistry showed no abnormal values in the treated mice at 4 weeks (data not shown), indicating that the combination therapy did not induce autoimmunity. To analyze the subset of activated lymphocytes, the frequency of tumor-responsive immune cells was determined by intracellular cytokine staining and flow cytometry. The percentage of CD4+ and CD8+ T cells stimulated to produce IFN-γ in response to Pan02 cells increased significantly in the mice treated by the combination therapy (Fig. 4b), indicating that this therapy enhances systemic antitumor immunity.

**Anti-glucocorticoid induced TNF receptor monoclonal antibody reduced Treg-accumulation in tumors.** It is known that a large number of tumor-infiltrating lymphocytes (TILs) result in a better antitumor effect for cancer patients. To examine whether an increase of TILs in treated tumors is related to tumor growth suppression, immunohistochemical staining of CD4+ and CD8+ cells was performed in the Pan02 tumors 13 days after the injection of Ad-mIFN. The intratumoral IFN-α expression significantly increased the infiltration of CD4+ and CD8+ T cells in both vector-injected and vector-uninjected tumors, and the anti-GITR mAb also increased the number of CD4+ cells in the both tumors (Fig. 5a,b). Furthermore, the combination therapy of anti-GITR mAb and IFN-α gene transfer further increased the infiltration of CD4+ and CD8+ cells compared with the Ad-mIFN or anti-GITR mAb alone groups (Fig. 5a,b). Next, the infiltration of Foxp3+ cells was assessed in the treated Pan02 tumors. Interferon-α gene transfer and anti-GITR mAb administration decreased the number of Foxp3+ cells in the tumors, and the combination therapy markedly decreased Foxp3+ cells (Fig. 5c). Since a high effective T cells/Tregs ratio is associated with a favorable prognosis for cancer patients, we calculated the ratio of CD4+ or CD8+ cells per Foxp3+ cells in the tumors. The ratios were markedly high in the combination therapy-treated tumors (Fig. 5d).

Then, to understand the proliferative status of lymphocytes infiltrated into tumors, we examined the Ki-67 expression on CD4+ and CD8+ T cells in regional lymph nodes and Pan02 subcutaneous tumors. Flow-cytometry showed that the frequencies of Ki-67+ cells per CD4+ and CD8+ T cells in the tumors were higher than those in the regional lymph nodes, indicating a significant population of CD4+ and CD8+ T cells in the tumors was in the state of proliferation, which may indicate that tumor-infiltrating T cells responded to tumor-associated antigens (Fig. 5e). Furthermore, the frequencies of Ki-67+CD4+ or CD8+ T cells in the tumors showed a tendency toward an increase in combination therapy-treated mice compared with non-treated mice. Since, in general, the lymphocytes are activated in lymph nodes, the results suggested that Pan02-responsive CD4+ and CD8+ T cells were activated in lymph nodes and infiltrated into the subcutaneous tumors.

**GITR mAb suppressed CCR5 expression on Tregs.** It was reported that CD4+Foxp3+ Tregs preferentially expressed CCR5 compared with CD4+Foxp3- effector T cells in a murine model of pancreatic cancer. To understand the mechanism of decreased Treg-accumulation in the tumors, the effect of GITR mAb on CCR5 expression of Tregs was analyzed. We first examined the expression of CCR5 ligands such as CCL3, CCL4 and CCL5 in Pan02 subcutaneous tumors. The RT-PCR analysis showed that the Pan02 tumor expressed CCL3, CCL4 and CCL5 in Pan02 subcutaneous tumors. The RT-PCR analysis showed that the Pan02 tumor expressed CCL3, CCL4 and CCL5, whereas the pancreas did not express the ligands except for CCL5 (Fig. 6a). Next, we analyzed the CCR5 expression on Tregs treated with anti-GITR mAb. Flow-cytometry showed that the percentage of CCR5+ Tregs in the spleens was approximately 7%, whereas that in the tumors was more than 30% (Fig. 6b), suggesting that a particular population of Tregs employed the interaction of CCR5-CCR5 ligands to infiltrate into Pan02 tumors. Then, we examined whether the anti-GITR mAb suppresses the CCR5 expression on Tregs. Flow-cytometry showed that the administration of anti-GITR mAb significantly decreased the CCR5 expression level on
Tregs in the spleen, which may explain the reduced number of Tregs infiltrating in the tumors (Fig. 6c). Furthermore, to examine the effect of GITR stimulation on CCR5 expression of Tregs and non-Tregs in vitro, the splenocytes were cultured with DTA-1 antibody at 1 μg/mL for 5 h. Flow-cytometry showed that the frequency of CCR5+ cells per CD4+Foxp3+ T cells was decreased approximately 80% of DTA-1-untreated cells, whereas that of CCR5+ cells per Foxp3+ Tregs was decreased <40% (Fig. 6d), suggesting that the GITR mAb suppressed the CCR5 expression on CD4+Foxp3+ Tregs more efficiently than that on CD4+ Foxp3− T cells.

**Discussion**

We have reported that an intratumoral type I IFN gene transfer induces a marked regional antitumor effect and systemic tumor immunity by the integrated antitumor effect including direct cytotoxicity, immune stimulation of NK cells and cytotoxic T lymphocytes, maturation and activation of DCs and the antiangiogenesis effect in several pancreatic cancer animal models. However, an immunotolerant microenvironment developed by cancer attenuates the antitumor immune response. In pancreatic cancer also, Hiraoka and colleagues reported that Tregs play an important role in controlling the immune response against pancreatic ductal carcinoma from the premalignant stage to established cancer, and that a high prevalence of Tregs is a marker of poor prognosis in pancreatic ductal carcinoma. This study showed that the immune stimulatory reactions by IFN-α gene transfer were significantly reinforced by the inhibition of an immunotolerant environment by anti-GITR mAb.

Antibodies that activate or neutralize immunostimulatory and immunoinhibitory factors show an exciting therapeutic potential in experimental models, and clinical trials with anti-CTLA-4, anti-programmed death-1, anti-programmed death-L1, anti-GITR, indole-2, 3 dioxygenase inhibitors, and other modulators of cancer immunosuppression are now under way. Among these modulators of cancer immunosuppression, we selected an agonistic anti-GITR antibody because, regarding Treg/effector T cell interplay, GITR triggering can have several distinct effects: (i) co-stimulation and activation of effector T cells, which in itself makes them more difficult to be inhibited; (ii) inhibition of Treg activity by decreasing molecules important for suppression; (iii) decrease of the specific sensitivity of effector T cells to Treg-mediated suppression; and (iv) partial depletion of Treg. Another intriguing
mechanism is that anti-GITR mAb significantly decreased the number of CD4⁺CD25⁺ Tregs infiltrating in tumor sites as shown in Fig. 5(c) and previous reports, suggesting that the GITR mAb creates an environment strongly supporting the enhancement of antitumor immunity. Mitsui et al. (29) reported that co-stimulatory signals through GITR may inhibit conver-
sion of CD4+CD25− effector T cells to Tregs, and that another possibility is that CD8+CD25high T cells infiltrating into tumors compete with CD4+CD25+ Tregs for availability of IL-2, because of the greater dependence of Tregs on IL-2 compared with effector T cells. In addition, we found that the in vivo CCR5 expression level on Tregs was significantly decreased by the administration of anti-GITR antibody, which may be a novel mechanism of Treg-inhibition in tumors.

A combination treatment of an anti-GITR mAb and intratumoral IFN-α gene transfer exhibited stronger antitumor effects compared with either treatment alone. Immunostaining of treated tumors showed that the anti-GITR mAb increased the number of CD8+ T cells and decreased Foxp3+ cells infiltrating in the tumors, while intratumoral IFN-α gene transfer increased both CD4+ and CD8+ T cells and also decreased the Foxp3+ cell in the tumors (Fig. 5a–c). Therefore, the combination treatment synergistically increased the number of effector T cells and markedly decreased Tregs in the tumors (Fig. 5d), and strongly inclined the immune balance of the tumor microenvironment in an antitumor direction, which should lead to a marked systemic antitumor effect. The precise mechanism for IFN-α-mediated inhibition of Tregs in tumors is not completely understood. Although we previously reported that an intratumoral IFN-α expression stimulates DCs to produce the cytokine IL-6,(17) which is a critical factor for suppressing Tregs, it would also be necessary to examine the direct effect of IFN-α on Tregs in tumors.

In this study, we used a subcutaneous tumor as a model of locally advanced pancreatic cancer, which is the main target of a local IFN-α gene therapy. Although locally advanced pancreatic cancer is defined as surgically unresectable with no evidence of distant metastasis, it is highly prone to metastasize during or after standard chemoradiotherapy. To provide a significant impact on long-term survival, locally advanced cancer also requires the improvement of both regional control and effective systemic treatment against the occurrence of distant metastasis. As shown in Fig. 3(a,b), the combination therapy significantly suppressed the growth of not only vector-injected tumors but also of vector-uninjected tumors, suggesting that the combination is a highly promising strategy for locally advanced pancreatic cancer.

With respect to the safety of the therapy, it is noteworthy that the IFN-α gene transfer showed a strong inhibitory effect and specific cell death induction on cancer cells including pancreatic cancer cells but not on normal cells such as hepatocytes and vascular endothelial cells.(11) In addition, there was a considerable difference in the IFN-α protein concentration between a vector-injected tumor tissue and the serum.(12,14) As one of the reasons for a little leakage of the IFN-α protein from the tumors into blood circulation, we reported that extracellular matrix proteins such as fibronecin in tumors directly interact with IFN-α and retain the cytokine.(30) Therefore, we expect the toxicity of a local IFN-α gene therapy to be tolerable in human clinical trials. On the other hand, although the anti-GITR mAb is effective in suppressing Tregs, a global Treg modulation by anti-GITR mAb may be undesirable, because it may increase susceptibility to autoimmunity.(20) Therefore, for the next research, the development of a strategy to inhibit Tregs in tumors alone will be important for developing an effective and safe immune therapy for cancers.

In summary, our preclinical study suggested that the combination of intratumoral IFN-α gene transfer and anti-GITR mAb is one of the promising new approaches to pancreatic cancer. The strategy may be worthy of an evaluation in a future clinical trial for this highly intractable cancer.

Acknowledgments
We thank Professor Shimon Sakaguchi, Immunoology Frontier Research Center, Osaka University, for providing a DTA-1 hybridoma. K Aida and T Udagawa are awardees of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research. This work was supported in part by a grant-in-aid for the 3rd Term Comprehensive 10-year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan, by grants-in-aid for research from the Ministry of Health, Labour and Welfare of Japan, by the program for promotion of Foundation Studies in Health Science of the National Institute of Biomedical Innovation, and by the National Cancer Center Research and Development Fund (23-A-38).

Disclosure Statement
The authors have no conflict of interest.

References
1 Hackert T, Buchler MW. Pancreatic cancer: advances in treatment, results and limitations. Dig Dis 2013; 31: 51–6.
2 Paulson AS, Tran Cao HS, Temporo MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013; 144: 1316–26.
3 Werner J, Combs SE, Springfield C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol 2013; 10: 323–35.
4 Okasaka T, Matsumura Y, Aoki K. New approaches for pancreatic cancer in Japan. Cancer Chemother Pharmacol 2004; 54 (Suppl. 1): S78–82.
5 Yoshida T, Ohnami S, Aoki K. Development of gene therapy to target pancreatic cancer. Cancer Sci 2004; 95: 283–9.
6 Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 2013; 27: 803–12.
7 Tachimi AA, Gogas H, Kirkwood JM. IFN-alpha in the treatment of melanoma. J Immunol 2012; 189: 3789–93.
8 Rosenblatt J, McDermott DF. Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: 793–812.
9 Santini SM, Lapenta C, Santodanote L, D’Agostino G, Belardelli F, Ferrantini M. IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb Exp Pharmacol 2009; 188: 295–317.
10 Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884–93.

11 Hatanaka K, Suzuki K, Miura Y et al. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004; 6: 1139–48.
12 Ohashi M, Yoshida K, Kushida M et al. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Br J Cancer 2005; 93: 441–9.
13 Hara H, Kobayashi A, Yoshida K et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci 2007; 98: 455–63.
14 Narumi K, Kondoh A, Udagawa T et al. Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer. Cancer Sci 2010; 101: 1686–94.
15 Udagawa T, Narumi K, Goto N et al. Syngeneic hematopoietic stem cell transplantation enhances the antitumor immunity of intratumoral type I interferon gene transfer for sarcoma. Hum Gene Ther 2012; 23: 173–86.
16 Hara H, Kobayashi A, Narumi K et al. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Immunother 2009; 58: 1007–13.
17 Narumi K, Udagawa T, Kondoh A et al. In vivo delivery of interferon-alpha gene enhances tumor immunity and suppresses immuno tolerance in reconstituted lymphopenic hosts. Gene Ther 2012; 19: 34–48.
18 Rabinirovich GA, Galibroff DC, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267–96.
19 Kobayashi N, Hiraoka N, Yamagami W et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902–11.

20 Byrne WL, Mills KH, Lederer JA, O’Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res 2011; 71: 6915–20.

21 Nocentini G, Ronchetti S, Cuzzocrea S, Riccardi C. GITR/GITRL: more than an effector T cell co-stimulatory system. Eur J Immunol 2007; 37: 1165–9.

22 Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135–42.

23 Nishikawa H, Kato T, Hirayama M et al. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 2008; 68: 5948–54.

24 Niwa H, Yamanura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193–9.

25 Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7: 4.

26 Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538–43.

27 Tan MC, Goedegebuure PS, Belt BA et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182: 1746–55.

28 Cohen AD, Schaer DA, Liu C et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 2010; 5: e10436.

29 Mitusi J, Nishikawa H, Muraoka D et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010; 16: 2781–91.

30 Yoshida K, Kondoh A, Narumi K, Yoshida T, Aoki K. Extracellular matrix interacts with interferon alpha protein: retention and display of cytotoxicity. Biochem Biophys Res Commun 2008; 376: 299–304.